Tempest Therapeutics, Inc. Proceeds from Stock Options Exercised
Tempest Therapeutics, Inc. (TPST) reported Proceeds from Stock Options Exercised of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2023-03-22
- Tempest Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2021-12-31 was $42.00K, a 35.48% increase year-over-year.
- Tempest Therapeutics, Inc. proceeds from stock options exercised for fiscal 2021 was $108.00K, a 56.52% increase from fiscal 2020.
- Tempest Therapeutics, Inc. proceeds from stock options exercised for fiscal 2020 was $69.00K.
- Tempest Therapeutics, Inc. proceeds from stock options exercised for fiscal 2017 was $2.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $42.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | $42.00K derived: sum of 3 quarters · filed 2023-03-22 | $91.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | $42.00K derived: sum of 2 quarters · filed 2023-03-22 | $91.00K derived: sum of 3 quarters · filed 2023-03-22 | $105.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2021-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $91.00K derived: sum of 2 quarters · filed 2023-03-22 | $105.00K derived: sum of 3 quarters · filed 2023-03-22 | $108.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $63.00K derived: sum of 2 quarters · filed 2022-11-08 | $66.00K 10-Q · filed 2022-11-08 | $97.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $17.00K 10-Q · filed 2022-08-15 | $48.00K derived: sum of 3 quarters · filed 2022-08-15 | $59.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-13 | $34.00K derived: sum of 2 quarters · filed 2022-05-13 | $45.00K derived: sum of 3 quarters · filed 2022-05-13 | -$6.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $42.00K derived: sum of 2 quarters · filed 2022-03-29 | -$9.00K derived: sum of 3 quarters · filed 2022-03-29 | $69.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$40.00K derived: sum of 2 quarters · filed 2021-11-10 | $38.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $27.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $78.00K 10-Q · filed 2020-05-08 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | |||
| 2017-12-31 | $2.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |